LY-272015 FREE BASE

Details

Stereochemistry	RACEMIC
Molecular Formula	C21H24N2O2
Molecular Weight	336.4275
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

COC1=CC=C(CC2NCCC3=C2NC4=CC=C(C)C=C34)C=C1OC

InChI

InChIKey=GDAJGLDMCDMPIR-UHFFFAOYSA-N

InChI=1S/C21H24N2O2/c1-13-4-6-17-16(10-13)15-8-9-22-18(21(15)23-17)11-14-5-7-19(24-2)20(12-14)25-3/h4-7,10,12,18,22-23H,8-9,11H2,1-3H3

HIDE SMILES / InChI

Molecular Formula	C21H24N2O2
Molecular Weight	336.4275
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: Cohen ML, Schenck KW, Mabry TE, Nelson DL, Audia JE (1996) LY272015, a potent, selective and orally active 5-HT2B receptor antagonist. J Ser Res 3:131–144. | https://www.ncbi.nlm.nih.gov/pubmed/8709108
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/10070078 | https://www.ncbi.nlm.nih.gov/pubmed/12235249

LY-272015 is an antagonist at serotonin 5-HT2B receptor. LY-272015 exerts antihypertensive action in animal models.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Serotonin 2b (5-HT2b) receptor 60 Target ID: CHEMBL1833 Sources: Cohen ML, Schenck KW, Mabry TE, Nelson DL, Audia JE (1996) LY272015, a potent, selective and orally active 5-HT2B receptor antagonist. J Ser Res 3:131–144. \| https://www.ncbi.nlm.nih.gov/pubmed/8709108	Antagonist 2778

Conditions

Condition	Modality	Targets	Highest Phase	Product
Hypertension 567 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10070078 https://www.ncbi.nlm.nih.gov/pubmed/12235249	Primary		Preclinical	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
5-HT2B-receptor antagonist LY-272015 is antihypertensive in DOCA-salt-hypertensive rats.	1999 Mar	10070078
Endogenous 5-HT2B receptor activation regulates neonatal respiratory activity in vitro.	2006 Aug	16758492
Expression and function of serotonin 2A and 2B receptors in the mammalian respiratory network.	2011	21789169
5HT(2A) and 5HT(2B) receptors contribute to serotonin-induced vascular dysfunction in diabetes.	2012	23346101

Patents

Sample Use Guides

In Vivo Use Guide

In chronically instrumented rats, the 5-HT2B-receptor antagonist LY-272015 (0.3, 1.0, and 3.0 mg/kg iv at 30-min intervals) was given cumulatively 1 time/wk during 4 wk of continued DOCA-salt treatment. LY-272015 did not reduce blood pressure of the sham-treated rats at any time or dose. However, LY-272015 (1.0 and 3. 0 mg/kg) significantly reduced mean blood pressure in a subgroup of week 3 (-20 mmHg) and week 4 DOCA-salt (-40 mmHg) rats that had extremely high blood pressure (mean arterial blood pressure approximately 200 mmHg).

Route of Administration: Intravenous

In Vitro Use Guide

LY272015 0.1 uM completely inhibited 5-HT or BW723C86 induced hepatocyte DNA synthesis and proliferation.

Substance Class	Chemical Created by `admin` on `Sat Dec 16 19:31:04 UTC 2023` Edited by `admin` on `Sat Dec 16 19:31:04 UTC 2023`
Record UNII	6W6AEG3W3E
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

LY-272015 FREE BASE

Common Name

English

1H-Pyrido[3,4-b]indole, 1-[(3,4-dimethoxyphenyl)methyl]-2,3,4,9-tetrahydro-6-methyl-

Systematic Name

English

1-[(3,4-Dimethoxyphenyl)methyl]-2,3,4,9-tetrahydro-6-methyl-1H-pyrido[3,4-b]indole

Systematic Name

English

1H-Pyrido[3,4-b]indole, 1-[(3,4-dimethoxyphenyl)methyl]-2,3,4,9-tetrahydro-6-methyl-, (±)-

Systematic Name

English

Code System Code Type Description

FDA UNII

6W6AEG3W3E